Q4 2025 LifeMD Inc Earnings Call Transcript
Key Points
- LifeMD Inc (LFMD) reported a strong fourth quarter and full year with solid performance across all business lines.
- The company entered 2026 with over 322,000 active subscribers, nearly $37 million in cash, and no debt, marking the strongest balance sheet in its history.
- LifeMD Inc (LFMD) successfully launched Oral Wegovy through a collaboration with Novo Nordisk, expanding access for patients preferring an oral option.
- The company's affiliated pharmacy is now licensed in all 50 states, processing approximately 20,000 prescriptions per month, enhancing its operational capabilities.
- LifeMD Inc (LFMD) is investing in AI and engineering to deploy advanced AI capabilities across care delivery, diagnostics, and patient operations, aiming to improve patient outcomes and unit economics.
- Despite strong performance, LifeMD Inc (LFMD) reported a GAAP net loss from continuing operations of $1.9 million for the fourth quarter of 2025.
- The company anticipates an adjusted EBITDA loss in the range of $4 million to $5 million for the first quarter of 2026 due to high patient acquisition costs in the GLP-1 weight loss business.
- LifeMD Inc (LFMD) is making significant discretionary marketing investments, which may impact short-term profitability.
- The women's health segment, while promising, is not expected to be EBITDA positive on a consolidated basis in its first year.
- The company faces competition from major players like Amazon and Lilly in the weight management space, which could impact market share.
Good afternoon. Thank you for joining us today to discuss LifeMD's results for the fourth quarter and full year ended December 31, 2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session.
Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected.
These risks and uncertainties are described in the company's 10-K and 10-Q filings and within other filings that LifeMD may take with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, March 9, 2026. The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Also, please note that management will be discussing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
